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Abstract
 
Immune responses induced during the early stages of chronic viral infections are thought to in-
fluence disease outcome. Using HIV as a model, we examined virus-specific cytotoxic T lym-
phocytes (CTLs), T helper cells, and viral genetic diversity in relation to duration of infection
and subsequent response to antiviral therapy. Individuals with acute HIV-1 infection treated
before seroconversion had weaker CTL responses directed at fewer epitopes than persons who
were treated after seroconversion. However, treatment-induced control of viremia was associ-
ated with the development of strong T helper cell responses in both groups. After 1 yr of anti-
viral treatment initiated in acute or early infection, all epitope-specific CTL responses persisted
despite undetectable viral loads. The breadth and magnitude of CTL responses remained signif-
icantly less in treated acute infection than in treated chronic infection, but viral diversity was
also significantly less with immediate therapy. We conclude that early treatment of acute HIV
infection leads to a more narrowly directed CTL response, stronger T helper cell responses,
and a less diverse virus population. Given the need for T helper cells to maintain effective CTL
responses and the ability of virus diversification to accommodate immune escape, we hypothe-
size that early therapy of primary infection may be beneficial despite induction of less robust
CTL responses. These data also provide rationale for therapeutic immunization aimed at
broadening CTL responses in treated primary HIV infection.
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Introduction
 
The outcome of many viral infections is containment rather
than the eradication of infection, suggesting a central role of
the immune system in viral control. Increasing data indicate
the importance of CTLs in HIV-1 infection (for reviews,
see references 1–3). During untreated primary infection,
HIV-1–specific CTL activity is associated with the initial
decrease of viremia (4–6) and in vitro studies have shown
 
potent inhibition of viral replication by CD8
 
1
 
 T cells, me-
diated by both lytic and nonlytic mechanisms (7). Studies in
individuals with long-term nonprogressing HIV-1 infec-
tion, in whom persistent low viral loads have been associ-
ated with strong CTL responses (8–11), and observations of
declining CTL responses in persons with disease progres-
sion (11–13), further support the potential important role of
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the cellular immune response. In addition, recent animal
model data have shown that CD8
 
1
 
 cell depletion is associ-
ated with an increase in viral load (14–16). The inverse cor-
relation between HIV-1–specific CTLs and viral load has
also been demonstrated by flow cytometry in untreated
persons with chronic HIV-1 infection using MHC class I
tetramers (10).
Despite the strong antiviral effect of CTLs, most HIV-1–
infected individuals have poorly controlled viremia and
progress to AIDS without effective antiretroviral therapy.
Several studies, predominantly in the murine lymphocytic
choriomeningitis virus model, indicate that maintenance of
effective CTLs requires the presence of virus-specific T
helper cells (17–19). Recent studies in HIV-1 infection,
showing an inverse association between virus-specific
CD4
 
1
 
 cell responses and viral load (20) and an association
between strong HIV-1–specific CTL and T helper cell re-
sponses (21) suggest that virus-specific T helper cells are
also required for maintaining an effective CTL response in
HIV-1 infection (for reviews, see references 1 and 22). As
T helper cell function is impaired early after HIV-1 infec-
tion (20, 23, 24), loss of T helper cell support may be an
important reason for subsequent insufficient virus control
by CTLs. Additional factors contributing to the failure of
the immune system to control HIV-1 infection observed in
the majority of infected individuals may be the generation
of viral escape mutants (25–29) and the development of
high viral diversity over time (30–33).
Several studies indicate that early antiviral therapy results
in the generation of strong HIV-1–specific T helper cell re-
sponses (20, 23, 34). However, effects of early therapy on
CTL responses, which are normally closely linked to T
helper cell responses in HIV infection (21), have not been
well defined. In addition, there is a paucity of data relating
overall viral diversity to immune responses in acute or
chronic viral infections. Here, we present a detailed analysis
of the HIV-1 epitope-specific cellular immune responses in
subjects that were treated with highly
 
 
 
active antiretroviral
therapy
 
 (
 
HAART)
 
1
 
 during acute HIV-1 infection, before
seroconversion, or within 180 d of HIV-1 infection. In ad-
dition, as viral diversification has been linked to disease
outcome in a chronic human viral infection (32, 35, 36),
we examine the diversity of the HIV-1–env C2-V5 region
in these subjects compared with those in individuals treated
during chronic HIV-1 infection.
 
Materials and Methods
 
Study Subjects.
 
A cohort of subjects with acute HIV-1 infec-
tion has been established at the Massachusetts General Hospital
and at the San Francisco General Hospital, the first 30 of whom
are reported here. These subjects were divided in two groups:
those individuals who were diagnosed and treated with HAART
before or at the time of HIV-1 seroconversion (referred to as
 
“preseroconversion acute HIV”, 
 
n 
 
5
 
 19) and those individuals
treated with HAART after HIV-1 seroconversion but within
180 d of primary HIV-1 infection (“postseroconversion primary
HIV”, 
 
n 
 
5
 
 11; reference 37).
Acute HIV-1 infection in the preseroconversion group (group
1) was defined by symptomatic disease, recent high risk exposure,
positive plasma HIV-1 RNA and either a negative HIV-1 ELISA
or a negative/indeterminate HIV-1 Western blot. 16 subjects in
this cohort had a negative HIV-1 ELISA at diagnosis of infection
and 3 (AC08, AC09, and AC26) had a weakly positive ELISA
but indeterminate Western blot. 18 were Caucasian and one was
Hispanic (18 male and 1 female), and mode of exposure to HIV-1
was sexual in all. Upon diagnosis of acute HIV-1 infection, all
subjects were treated with HAART, including two nucleoside
analogues and either a protease inhibitor (
 
n
 
 
 
5
 
 14) or a nonnucle-
oside reverse transcriptase (RT) inhibitor (
 
n
 
 
 
5
 
 5). Individuals in
the postseroconversion primary HIV-1 group (group 2) were en-
rolled and treated with HAART within 180 d of HIV-1 infec-
tion (37). All individuals had fully seroconverted when HAART,
including two nucleoside analogues and either a protease inhibi-
tor or a nonnucleoside RT inhibitor, was started. Recent sero-
conversion was determined by either documentation of a nega-
tive HIV Ab test within the prior 180 d or a history consistent
with recent infection supported by laboratory evidence consisting
of a nonreactive less-sensitive enzyme immunoassay (EIA) Ab test
(37). 9 individuals were Caucasian and 2 were Hispanic (all male)
and mode of exposure to HIV-1 was sexual in 10 subjects and by
intravenous drug use in 1 subject. All individuals were adherent
to their treatment during the study period except individual
AC22, who was not fully adherent to the antiretroviral regiment.
For comparison, another group of 10 individuals who were
treated during chronic HIV-1 infection (“chronic HIV” group;
group 3) was studied. For these subjects, no pretreatment samples
were available, but only a single time point after at least 7 mo
(median 20 mo, range 7–38 mo) of effective antiretroviral treat-
ment resulting in an undetectable viral load. These individuals
were infected for at least 12 mo (median 2 yr, range 1–10 yr) be-
fore HAART, including two nucleoside analogues and either a
protease inhibitor or a nonnucleoside RT inhibitor, was started.
Seven individuals were Caucasian and three were of African de-
scent (eight male and two female) and mode of exposure to HIV-1
was sexual in all subjects studied.
This study was approved by the Massachusetts General Hospi-
tal and University of California at San Francisco Institutional Re-
view Boards and all individuals gave informed consent for partic-
ipation in the study.
 
HLA Typing.
 
HLA typing was performed at the Massachu-
setts General Hospital Tissue Typing Laboratory and at the
Department of Human Genetics, Roche Molecular Systems
(Alameda, CA) using sequence-specific primer (SSP)-PCR (38).
 
Viral Load Monitoring.
 
Plasma viral loads were measured us-
ing either the Roche Amplicor Monitor assay (detection limit of
400 HIV-1 RNA copies/ml plasma) or the Roche Ultradirect as-
say (detection limit of 50 HIV-1 RNA copies/ml plasma), ac-
cording to the manufacturer’s specifications.
 
Cell Lines and Media.
 
EBV-transformed B lymphoblastoid
cell lines (B-LCLs) were established and maintained in R20 me-
dium (RPMI 1640; Sigma-Aldrich) supplemented with 2 mM
 
l
 
-glutamine, 50 U/ml penicillin, 50 
 
m
 
g/ml streptomycin, 10 mM
Hepes, and 20% heat-inactivated FCS; Sigma-Aldrich) as de-
scribed (39). For culture of CTL clones, medium containing 10%
FCS (R10) supplemented with 50 U/ml rIL-2 (provided by Dr.
M. Gately, Hoffmann-La Roche, Nutley, NJ) was used.
 
1
 
Abbreviations used in this paper:
 
 Elispot, enzyme-linked immunospot;
HAART, highly active antiretroviral therapy; HMA, heteroduplex mo-
bility assay; RD, relative diversity; RT, reverse transcriptase; SFC, spot-
forming cell; SI, stimulation index. 
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Generation of CTL Clones.
 
CTL clones were isolated by lim-
iting dilution and characterized and maintained as described (40,
41) using the CD3-specific mAb 12F6 as stimulus for T cell pro-
liferation. Developing clones were screened for HIV-1–specific
CTL activity by 
 
51
 
Cr release assay (39) against autologous B cell
lines pulsed with peptides recognized in the enzyme-linked im-
munospot (Elispot) assays. Fine mapping of the novel CD8
 
1
 
 T
cell responses identified in the Elispot assay was achieved in a
 
51
 
Cr release assay using truncations of the recognized 15–20-mer
peptide as described (40).
 
Synthetic HIV-1 Peptides.
 
Peptides corresponding to de-
scribed optimal HIV-1 CTL epitopes (42) were synthesized on an
automated peptide synthesizer (model 432A; Applied Biosys-
tems). In addition, a panel of 259 overlapping peptides, 15–20
amino acids in length and overlapping by 10 to 11 amino acids,
spanning the entire p17 Gag, p24 Gag, gp41 Env, gp120 Env,
RT, and Nef B-clade SF2 sequence, were used. These peptides
were provided in part by the National Institute for Biological
Standards and Control Centralized Facility for AIDS Reagents,
supported by European Union Program EVA and the UK Medi-
cal Research Council.
 
Elispot Assay.
 
Fresh or frozen PBMCs were plated in 96-well
polyvinylidene difluoride–backed plates (MAIP S45; Millipore)
that had been coated previously with 100 
 
m
 
l of an anti–IFN-
 
g
 
mAb 1-D1k (0.5 
 
m
 
g/ml; Mabtech) overnight at 4
 
8
 
C. Peptides
were added directly to the wells at a final concentration of 10
 
2
 
5
 
 M.
Cells were added to the wells at 25,000–200,000 cells/well.
The plates were incubated at 37
 
8
 
C, 5% CO
 
2
 
 overnight (14–16 h)
and then processed as described (43, 44). IFN-
 
g
 
–producing cells
were counted by direct visualization and are expressed as spot-
forming cells (SFCs) per 10
 
6
 
 cells. The number of specific IFN-
 
g
 
–secreting T cells was calculated by subtracting the negative
control value from the established SFC count. The negative con-
trols were always 
 
,
 
30 SFCs/10
 
6
 
 input cells (median 5, range
0–25 SFCs/10
 
6
 
 input cells). The positive control consisted of in-
cubation of 100,000 PBMCs with phytohemagglutinin (PHA).
CD8
 
1
 
 T cell dependence of all responses to synthetic peptides
was confirmed by loss of IFN-
 
g
 
 production after CD8
 
1
 
 T cell
depletion using magnetic beads (MACS; Miltenyi Biotech), ac-
cording to the manufacturer’s protocol.
 
HIV-1–specific T Helper Cell Assays.
 
Lymphocyte prolifera-
tion assays were performed with baculovirus-derived HIV-1 Gag
protein (20). PBMCs were incubated with Gag protein (5 
 
m
 
g/
ml) for 6 d and then pulsed with [
 
3
 
H]thymidine at 1.0 
 
m
 
Ci/well
for 6 h, as described (20). For the purposes of data interpretation,
a stimulation index (SI) of 5 or greater was considered significant.
 
Heteroduplex Mobility Assay for the Evaluation of HIV-1 Genetic
Heterogeneity.
 
Assessing quasispecies complexity requires the
number of amplifiable templates in a specimen to be determined.
This is especially important in individuals with low viral load
where limited sampling of unique viral templates may lead to in-
accurate low estimates of viral diversity (45). DNA was extracted
from PBMCs from 37 of the 40 individuals (insufficient samples
were available for 3 persons) using Isoquick DNA extraction kit
(Orca Research). The proviral DNA encoding the C2-V5 region
of env was amplified by a nested PCR amplification strategy us-
ing primer pairs ED31-BH2 in the first round and DR7-DR8 in
the second round. Primer sequences for ED31, DR7, and DR8
have been described previously (31, 45); primer BH2 is 7759-5
 
9
 
-
CCTTGGTGGGTGCTACTCCTAATGGTTCA, where the
number corresponds to the position in the HXB2 genome (se-
quence data available from GenBank/EMBL/DDBJ under acces-
sion no. K03455) of the 5
 
9
 
 nucleotide. The first and second
 
round amplification conditions were 3 cycles of 95
 
8
 
C for 1 min,
55
 
8
 
C for 1 min, 72
 
8
 
C for 1 min, followed by 32 cycles of 94
 
8
 
C
for 15 s, 55
 
8
 
C for 45 s, 72
 
8
 
C for 1 min, and a final extension at
72
 
8
 
C for 5 min. Three serial fivefold dilutions of PBMC DNA
were amplified in triplicate by nested PCR and the results were
used to estimate HIV-1 proviral copy number using the program
Quality (46). Based on the presence of sufficient numbers of viral
templates in PBMCs, seven patients in each group were selected
for evaluation of viral heterogeneity by heteroduplex mobility as-
say
 
 
 
(HMA). The first round PCR products were pooled from an
average of 65 copies of viral template in each patient and ampli-
fied using second round primers. PBMC samples yielding 
 
,
 
20
copies of proviral templates were not used in analysis. The 700-
bp products from the second round were subjected to HMA (47)
on a 5% polyacrylamide gel electrophoresed at 200 V for 3 h. The
gels were stained with ethidium bromide and photographed on a
UV transilluminator (GelDoc system; Bio-Rad Laboratories).
Pixel intensity and the relative position of bands were quantitated
using NIH Image v1.62 (http://rsb.info.nih.gov/nih-image). Es-
timates of viral diversity were made based on the intensity and
relative migration of heteroduplexes. In brief, pixel intensities
were multiplied by the relative migration at that position and
summed over the entire lane to represent the average pairwise
DNA distance.
 
Statistical Analysis.
 
Statistical analysis and graphical presenta-
tion was done using SigmaPlot 5.0 (SPSS Inc.). Results are given
as mean 
 
6
 
 SE or median with range. Statistical analysis of signifi-
cance (
 
P 
 
values) were based on a two-tailed 
 
t
 
 test.
 
Online Supplemental Data Section.
 
CTL epitopes and fre-
quency of recognition at 0–12 mo of HAART in the individuals
studied are shown in online supplemental Tables S1–S3. The dif-
ferences in recognition of these CTL epitopes in the different
groups studied is shown in online supplemental Tables S4 and S5.
Online supplemental material is available at http://www.jem/
org/cgi/content/full/193/2/169/DC1.
 
Results
 
Plasma Viral RNA Levels in the Subjects Studied.
 
The 30
subjects with primary HIV-1 infection were divided into
two groups, according to the time between HIV-1 infec-
tion and initiation of antiretroviral treatment. Median
HIV-1 RNA plasma load before initiation of therapy in the
19 individuals of the preseroconversion acute HIV-1 group
was 7 
 
3
 
 10
 
6
 
 copies/ml (range 0.25 
 
3
 
 10
 
6
 
–95.5 
 
3
 
 10
 
6
 
 cop-
ies/ml) and median CD4
 
1
 
 T cell counts were 395 cells/
mm
 
3
 
 (range 42–1,023 cells/mm
 
3
 
). In the postseroconver-
sion primary HIV group (37), median HIV-1 RNA plasma
load before initiation of treatment was 10
 
5
 
 copies/ml
(range 500–8.3 
 
3
 
 10
 
5
 
 copies/ml) and median CD4
 
1
 
 T cell
counts were 544 cells/mm
 
3
 
 (range 314–981 cells/mm
 
3
 
).
 
Analysis of HIV-1–specific CTL Responses in Acute and
Early HIV Infection.
 
To maximally detect CTL responses
to potentially novel epitopes, PBMCs from all subjects were
screened with 259 individual overlapping 15–20-mer pep-
tides spanning the protein sequences of HIV-1 p17, p24,
RT, gp41, gp120, and Nef, using an Elispot assay. In addi-
tion, a median of 19 (range 2–33) described optimal HIV-1
CTL epitope peptides per individual were tested for recog-
nition, depending on the individual’s HLA type (42).
CD8
 
1
 
 T cell dependence of responses to overlapping pep- 
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tides was confirmed by CD41 and CD81 cell depletion
studies (data not shown). For each response to an overlap-
ping peptide, the optimal CTL epitope contained within
the 15–20 mer was characterized and used for the subse-
quent quantification of CTL responses. This approach, us-
ing overlapping peptides as well as described optimal CTL
epitopes for the corresponding HLA class I type, is exem-
plified for one patient in Fig. 1, A and B. Furthermore,
peptide-specific CTL lines or clones were generated in or-
der to confirm that the peptide-specific responses measured
by Elispot assay were reflective of cytotoxic activity in a
standard  51Cr release assay (Fig. 1, C, D, and E).
The data in Fig. 1, A and B show CTL responses to the
longer peptides and the subsequently defined optimal
epitopes for subject AC01. For each of the three epitope-
specific responses defined, the level of reactivity was greater
than the response to the larger peptide containing the opti-
mal epitope. To more comprehensively address this obser-
vation, we compared the magnitude of HIV-1–specific
CTL responses against overlapping peptides (15–20 mer)
directly to responses against the corresponding optimal
HIV-1 CTL epitopes (8–10 mer) for all epitopes defined in
all 30 subjects. A total of 62 different epitope-specific re-
sponses were detected, including 6 novel epitopes first de-
scribed here (see below). All responses that were detectable
with the optimal epitopes were also detected using the
overlapping peptides containing the corresponding optimal
sequence. Furthermore, the magnitude of responses to
overlapping peptides correlated significantly (R 5 0.7, P ,
0.001) to the responses to the corresponding optimal
Figure 1. HIV-1–specific CTL re-
sponses determined by screening PBMCs
in an Elispot assay using overlapping
peptides (15–20 mer) spanning HIV-1
p17 (Gag), p24 (Gag), RT, gp41 (Env),
gp120 (Env), and Nef sequences (A,
black bars) and reported or subsequently
defined optimal epitopes (B, gray bars).
CTL magnitudes are expressed as SFCs/
106 PBMCs. B shows all the previously
reported and newly defined optimal
CTL epitopes described for the HLA-
type of the individual (AC05: HLA-
A3/-, B14/60, Cw3/8). These epitopes
are contained in the corresponding
overlapping peptides in A. In C–E, the
cytolytic activity of CTL clones isolated
for the three epitopes recognized in this
individual in p24 (Gag), gp41 (Env), and
Nef is shown. Lytic activity is given as
percentage of specific lysis at two differ-
ent E/T ratios for autologous target cells
either pulsed or not pulsed with the
corresponding peptide. In F, the corre-
lation between CTL responses to opti-
mal HIV-1 CTL epitopes (9 to 10 mer)
and corresponding overlapping peptides
(15–20 mer) including the sequence of
the optimal CTL epitope is shown.
Each optimal epitope/overlapping pep-
tide pair is represented by a single dot
and frequencies are given as SFCs/106
PBMCs.173 Altfeld et al.
epitopes (Fig. 1 F). However, responses were significantly
higher when the optimal CTL epitope was used (median
440 SFCs/106 PBMCs, range 0–2,240) compared with
the larger peptides (median 240 SFCs/106 PBMCs, range
0–1,400; P , 0.0001). None of the individuals recognized
all epitopes tested for their HLA class I type. Taken to-
gether, these results show optimal peptides are more sensi-
tive for detecting responses, but that the use of only previ-
ously described epitopes would lead to underestimation of
CTL responses in HIV-1 infection, both in acute and early
infection.
Longitudinal Changes of HIV-1–specific CTL Responses un-
der HAART. HIV-1–specific CTL responses in the indi-
viduals treated before seroconversion (group 1, preserocon-
version acute HIV) and in the individuals treated within
180 d of HIV-1 infection (group 2, postseroconversion pri-
mary HIV) were analyzed longitudinally during the first
year of treatment with HAART. Overall CTL frequencies,
represented by the total reactivity against all reported and
newly defined optimal HIV-1 peptides, are shown in Fig.
2, A and B. The individual data from which these figures
are derived are in online supplemental Tables S1 and S2.
Pretreatment HIV-1–specific CTL responses were of lower
magnitude in the individuals treated preseroconversion,
compared with the individuals treated postseroconversion
(210 6 115 SFCs/106 PBMCs vs. 778 6 1,021 SFCs/106
PBMCs, P , 0.05). Furthermore, fewer HIV-1 CTL
epitopes were targeted at baseline in the preseroconversion
group than in those identified postseroconversion (0.5 vs.
2.5 targeted, P 5 0.06). In both groups, the magnitude of
HIV-1–specific CTL responses increased significantly after
initiating antiretroviral treatment from baseline to 2 mo af-
ter starting HAART (Fig. 2, A and B). CTL frequencies
subsequently declined over the following 10 mo of treat-
ment. The significant differences between pre- and postse-
roconversion group in the magnitude of CTL responses
observed at baseline were lost after initiation of antiretrovi-
ral treatment. At 12 mo of HAART, the mean CTL re-
sponses were comparable in both groups (518 6 129
SFCs/106 PBMCs in the preseroconversion group and
600 6 203 SFCs/106 PBMCs in the postseroconversion
group; P 5 0.73).
In parallel to the increase in CTL magnitude in the pre-
seroconversion acute HIV-1 group after the initiation of
antiretroviral treatment, the number of recognized optimal
HIV-1 CTL epitopes increased from a median of 0.5
epitopes per person recognized at baseline (range 0–6) to a
median of 2 epitopes per person at 2 mo (range 0-7, P 5
0.005). Overall, the total number of CTL epitopes targeted
more than doubled from 20 epitopes pretreatment to 44
epitopes at 2 mo, and no established responses were lost
(see online supplemental Tables S1 and S2 for individual
responses). No further broadening of CTL responses was
observed after the 2-mo time point in these persistently
treated individuals. In the individuals treated after serocon-
version, but within 180 d of infection, this increase in the
number of CTL epitopes was less pronounced, augmenting
from a median of 2.5 CTL epitopes (total 23 epitopes,
range 0–5 per person) to a median of 3 epitopes (total 35
epitopes, range 0–7 per person, P 5 0.08) in the 11 sub-
jects studied (Fig. 2 B). Again, none of the established CTL
responses against HIV-1–specific epitopes was lost during
the observation period of 12 mo (online supplemental Ta-
bles S1 and S2).
Broadening of Virus-specific CTL Responses with Prolonged
Exposure to HIV-1. To compare the HIV-1–specific CTL
responses in subjects treated during early infection to CTL
responses in individuals treated during chronic infection,
the breadth and magnitude of CTL responses were ana-
lyzed using the same comprehensive approach in 10 chron-
ically infected individuals, who were effectively treated for
at least 7 mo with HAART (group 3, online supplemental
Figure 2. (A) Longitudinal CTL frequencies in persons with acute
HIV-1 infection. Mean total CTL frequencies directed against optimal
CTL epitopes and standard error for the 19 subjects treated before HIV-1
seroconversion (group 1, preseroconversion acute HIV) during acute
HIV-1 infection before treatment (0 mo) and after 2, 6, and 12 mo of
treatment with HAART are shown as SFCs/106 (Mill) PBMCs. The me-
dian number of optimal HIV-1 CTL epitopes recognized is indicated by
the number within the bar. Significance of differences between mean to-
tal CTL frequencies were calculated by two-tailed paired t test and only P
values , 0.05 are shown. (B) Longitudinal CTL frequencies in persons
with early HIV-1 infection. Mean total CTL frequencies directed against
optimal CTL epitopes and standard error for the 11 subjects treated after
HIV-1 seroconversion, but within 180 d of infection (group 2, postsero-
conversion primary HIV) before treatment (0 mo) and after 2, 6, and 12
mo of treatment with HAART are shown as SFCs/106 PBMCs. The me-
dian number of optimal HIV-1 CTL epitopes recognized is indicated by
the figure within the bar. Significance of differences between mean total
CTL frequencies were calculated by two-tailed paired t test and only P
values , 0.05 are shown.174 HIV-1–specific CTL Responses
Table S3). The mean HIV-1–specific CTL response at this
time point in subjects treated during chronic infection
(2458 6 521 SFCs/106 PBMCs) was significantly higher
than those seen at 6 or 12 mo of treatment in group 1 (P 5
0.01 and 0.0002) or group 2 (P 5 0.07 and 0.02), respec-
tively. Furthermore, CTLs in group 3 targeted a signifi-
cantly greater number of HIV-1–specific CTL epitopes
than the group 1 individuals receiving immediate treatment
of acute infection (median 5.5 epitopes, range 0–13 vs. me-
dian 2 epitopes, range 0–7; P 5 0.03; Fig. 3 A). The me-
dian breadth of CTL responses in the group 2 individuals
treated within 180 d of infection was three epitopes (range
0–7) and was not significantly different compared with in-
dividuals treated during acute or chronic infection (P 5
0.25 and 0.1, respectively). Taken together, these data are
consistent with a broadening of virus-specific CTL re-
sponses with prolonged exposure to presumably more di-
versified HIV-1 antigens.
Lack of HIV-1–specific T Helper Cells despite Persistent CTL
Responses in Chronic HIV-1 Infection. Several studies have
shown that HIV-1–specific T helper cell responses play an
important role in the effectiveness and maintenance of
HIV-1–specific CTL responses (for reviews, see references
1 and 22). To address the influence of the time of initiation
of antiretroviral therapy on HIV-1–specific T helper cell
responses, Gag-specific T helper cell responses were quan-
tified in a standard lymphoproliferation assay after 12 mo of
treatment in the two primary infection groups and the
chronically infected group (Fig. 3 B). Samples of 12/19 in-
dividuals from the preseroconversion acute HIV group,
8/11 samples from the postseroconversion primary HIV
group, and 10/10 samples from the group of individuals
with chronic HIV-1 infection were available for analysis
(Fig. 3 B). The T helper cell responses of most individuals
treated before seroconversion and two individuals treated
postseroconversion (AC10 and AC14) have been described
in part elsewhere (48).
Gag-specific T helper cell responses were undetectable
or of low magnitude in the individuals treated during
chronic HIV-1 infection (SI: 8 6 3; Fig. 3 B). In contrast,
significantly stronger T helper cell responses to Gag were
generated by the individuals treated during acute HIV-1
infection (SI: 43 6 13, P 5 0.02) or individuals treated
within 180 d of HIV-1 infection (SI: 29 6 10, P 5 0.05).
The differences in Gag-specific T helper cell responses be-
tween the two groups of primary infected subjects did not
reach statistical significance (P 5 0.4). The lack of detect-
able responses in chronically infected subjects is in line with
the previously reported lack of detectable HIV-1–specific
T helper cell responses in persons with chronic progressive
HIV-1 infection using this assay (20, 23, 24). Overall, these
data confirm previous reports demonstrating the generation
of strong HIV-1–specific T helper cell responses in individ-
uals treated during acute HIV-1 infection (20), and show
that this immune response can be achieved in both acute
and early infection.
Lack of Viral Diversification in Individuals Treated during
Acute HIV-1 Infection. The data on the cellular immune
responses directed against HIV-1 described above show
that early initiation of antiretroviral treatment, before HIV-1
seroconversion, leads to the generation of strong Gag-
specific T helper cell responses, which otherwise are typi-
cally absent or low in infected persons. In contrast to T
helper cells, HIV-1–specific CTL responses are weaker and
more narrowly directed in the early treated subjects com-
pared with persons treated in chronic infection. The effect
of early or late treatment of HIV-1 infection on the diver-
sity of the virus was therefore addressed, using the HMA
focused on the env C2-V5 region (47).
After effective treatment with HAART for 6–12 mo,
samples of 37 from the 40 individuals were analyzed, and in
21 individuals (7 from each group) sufficient amounts of
proviral DNA were isolated to perform heteroduplex anal-
ysis. HIV-1 envelope genes had very low levels of diversity
Figure 3. (A) Breadth of CTL responses in HIV infection: the number
of optimal HIV-1–specific CTL epitopes recognized in each individual
studied after 1 yr of treatment with HAART is shown as a single dot.
Breadth of CTL responses was compared between the persons with
treated acute HIV-1 infection (preseroconversion [pre-SC]; n 5 19), the
persons treated postseroconversion (post-SC), but within 180 d of infec-
tion (n 5 11), and the persons first treated in the chronic phase of infec-
tion (chronic; n 5 10). A horizontal line indicates median number of rec-
ognized CTL epitopes for each group, and significance of differences
between the groups was calculated by two-tailed t test. (B) T helper cell
responses in HIV-1 infection: HIV-1 Gag-specific T helper cell responses
were assessed among persons with treated acute HIV-1 infection (prese-
roconversion; n 5 19) after 1 yr on therapy. These were compared with
HIV-1 Gag-specific T helper cell responses in persons treated postsero-
conversion, but within 180 d of infection (n 5 11) and persons first
treated in the chronic phase of infection (n 5 10). A horizontal line indi-
cates the mean SI for each group and significance of differences between
the groups was calculated by two-tailed t test.175 Altfeld et al.
in six of the seven individuals treated before HIV-1 sero-
conversion, all of whom were highly adherent to medica-
tion regimens (relative diversity [RD] 5 2.7 6 0.3; Fig. 4).
The seventh individual in this group (AC22) had a higher
level diversity (RD 5 3.4), associated with poor adherence
to his antiretroviral drug regimen, and several viral re-
bounds during the first year of treatment. However, HIV-
1–specific CTL responses did not increase in magnitude or
breadth during or after the period of poor adherence in this
single individual (online supplemental Table S1). In con-
trast, the individuals treated within 180 d of HIV-1 infec-
tion or during chronic infection showed significantly
higher diversity in the env gene of the virus (RD 5 3.3 6
0.5, P , 0.03 and 3.7 6 0.5, P , 0.001, respectively; Fig.
4). Differences in viral diversity between the two latter
groups did not reach statistical significance (P 5 0.14).
Taken together these data indicate that the generation of
genetic variants of HIV-1 may be reduced by the very early
initiation of antiretroviral treatment with effective suppres-
sion of viral replication.
The Breadth of HIV-1–specific CTL Responses Is Inversely
Correlated to Viral Load during Acute Infection. The tempo-
ral association of the initial decline in viremia during acute
HIV-1 infection and the first development of virus-specific
CTL responses has been described in several studies (4, 5).
To investigate whether the breadth of CTL responses was
associated with early viral load, the epitope-specific CTL
responses in individuals with primary HIV-1 infection
were compared with viral load before initiation of antiret-
roviral treatment. The breadth of the CTL responses was
inversely associated with the viral load at presentation in
the subjects treated before HIV-1 seroconversion (R  5
0.54, P , 0.02; Fig. 5 A). In contrast, no significant corre-
lation between viral load and breadth of CTL responses at
the time of presentation was observed in the subjects who
were treated after seroconversion, within the first 180 d of
infection (R 5 0.22, P 5 0.5; Fig. 5 B). Furthermore, we
observed no correlation between CTL magnitude and
plasma HIV-1 RNA levels, CD41 T cell counts or HIV-1–
specific T helper cell responses at 12 mo of treatment in
Figure 4. Viral diversification using the HMA focused on the env C2-
V5 region: diversification of the HIV-1 env C2-V5 region is shown for
persons with treated acute HIV-1 infection (preseroconversion [pre-SC]),
persons treated postseroconversion, but within 180 d of infection (post-
SC) and persons first treated in the chronic phase of infection (chronic) in
A. B shows the RD measured by HMA for the seven individuals of each
group, for whom sufficient amounts of proviral DNA was isolated to per-
form analysis (1, AC16; 2, AC01; 3, AC03, 4, AC04, 5, AC09; 6, AC13;
7, AC22; 8, AC14; 9, AC10; 10, AC25; 11, AC21; 12, AC29; 13,
OP286; 14, OP314; 15, 6001; 16, 6002; 17, 6003; 18, 6006; 19, 6007;
20, 6009; and 21, 6010).
Figure 5. Correlation between baseline HIV-1 RNA load (copies per
ml plasma) before the initiation of treatment and the number of optimal
HIV-1 CTL epitopes recognized for persons with treated acute HIV-1
infection (A, n 5 19) and persons treated postseroconversion, but within
180 d of infection (B, n 5 11).176 HIV-1–specific CTL Responses
either group. These data indicate a negative correlation be-
tween breadth of CTL responses and viral load in the earli-
est phase of HIV-1 infection during the initial reduction of
HIV-1 viremia.
Qualitative Differences in HIV-1–specific CTL Responses
during Acute and Chronic Infection. After assessing quantita-
tive differences in CTL responses to HIV-1 depending on
the time between infection and initiation of antiretroviral
treatment, differences in the CTL-recognition of specific
regions of HIV-1 were addressed. Table I shows the per-
centage of individuals with CTL responses directed against
different regions of HIV-1. Independent of the time point
of initiation of HAART, HIV-1–Gag was preferentially
targeted by HIV-1–specific CTLs, followed by HIV-1–
Env and HIV-1–Nef. HIV-1–RT was recognized by CTLs
in only 17–20% of individuals with acute or early infection,
but was as frequently recognized as HIV-1–Env (40%) in
the individuals treated during chronic infection.
Discussion
Accumulating data indicate that the antiviral immune ac-
tivity generated in acute infection may be critical for deter-
mining the ultimate progression of disease (49–51). A bet-
ter understanding of the dynamic interactions between
HIV-1 and the human immune system during acute infec-
tion is therefore crucial for defining the role of host defense
mechanisms in controlling viremia. To date the analysis of
HIV-1–specific immune responses has been dominated by
studies in chronic infection. In this study, epitope-specific
CTL responses against HIV-1 were prospectively analyzed
in individuals identified during acute and early HIV-1
infection and compared after treatment to responses in
treated chronically infected individuals. Furthermore, HIV-
1–specific T helper cell responses and the diversity of the
HIV-1–env gene were also compared between these differ-
ent cohorts after treatment with HAART.
An increase of HIV-1–specific CTL responses was ob-
served with longer exposure to viral antigen. In individuals
treated during acute HIV-1 infection before seroconver-
sion virus–specific CTL responses were weaker and more
narrowly directed against fewer epitopes than in individuals
treated during chronic HIV-1 infection. These data indi-
cate that the very early initiation of effective antiretroviral
treatment before seroconversion, when HIV-1–specific
CTL responses were still developing, may have inhibited a
further broadening of CTL responses. This finding is fur-
ther supported by preliminary longitudinal data on HIV-1–
specific CTL responses in individuals who were not treated
during acute infection. These individuals experienced an
increase in breadth and magnitude of CTL responses over
the first 6 mo of follow up (Altfeld, M., unpublished data).
Our findings of weak CTL responses in acute HIV-1 infec-
tion are consistent with more limited cross-sectional data of
Dalod et al., in which the breadth of responses was less ex-
tensively characterized (52). Using overlapping peptides
spanning p17 (Gag), p24 (Gag), RT, gp41 (Env), gp120
(Env), and Nef in this study along with an extensive set of
optimal epitopes, detailed longitudinal assessment of both
breadth and magnitude of CTL responses during acute
HIV-1 infection could be defined. This approach allowed
the identification of 6 novel CTL epitopes, representing al-
most 10% of the total of 62 different CTL epitopes that
were recognized by the 40 individuals studied. Responses
to these novel CTL epitopes contributed importantly to
the breadth of CTL responses in 6 of the 30 individuals
with acute and early HIV-1 infection, representing 13–
100% (median 47%) of the recognized CTL epitopes in
these subjects. These data indicate that CTL responses in
acute and early HIV-1 infection would have been underes-
timated with the use of reported optimal epitopes alone.
The comprehensive analysis of CTL epitopes also al-
lowed us to identify differences in epitopes targeted in early
and later stages of HIV infection, and the effects of
HAART on these responses (summarized in online supple-
mental Tables S4 and S5). Only 1 of the 10 HLA-A2–posi-
tive subjects with acute infection recognized the p17
epitope SLYNTVATL (10%), in contrast to 2/6 individuals
(33%) treated within 180 d of infection and 2/4 individuals
(50%) treated during chronic infection (summarized in on-
line supplemental Tables 4 and 5). The low frequency of
recognition of this epitope by individuals expressing HLA-
A2 during acute HIV-1 infection is in striking contrast to
the higher frequency of recognition seen in the limited
number of chronically infected individuals included in this
study, as well as to data derived from published studies in
chronically HIV-1–infected subjects, in whom SLYNT-
VATL is targeted in z70% (10, 53–55). The response to
this epitope may only develop after a longer period of ex-
posure to the antigen, which has been shortened in this
study by the early initiation of HAART (56). A similar pat-
tern of increased recognition of CTL epitopes in later
treated individuals was observed for the other HLA-A2–
restricted epitopes, the HLA-B44–restricted epitope in
gp120, and the HLA-B8–restricted epitopes in p17 and RT
(online supplemental Tables 4 and 5). In contrast, the
HLA-A3–restricted epitopes as well as the HLA-B8–
restricted CTL epitopes in p24 and Nef were frequently
Table I. Percentage of Individuals with CTL Responses against 
Specific HIV-1 Proteins
p17 p24 Gag RT gp41 gp120 Env Nef
Pre-SC Baseline 22 11 33 17 17 11 28 17
12 mo 33 33 61 16 28 17 39 56
Post-SC Baseline 40 50 70 0 40 20 50 40
12 mo 50 60 80 20 40 30 50 40
Chronic 12 mo 50 70 80 40 20 30 40 50
Overall percentages for the entire protein are indicated in bold. Pre-SC,
preseroconversion; post-SC, postseroconversion.177 Altfeld et al.
recognized in individuals with acute HIV-1 infection (on-
line supplemental Tables 4 and 5). The differences in fre-
quency of recognition of specific CTL epitopes in acute
compared with chronic HIV-1 infection indicate that cer-
tain epitopes are more immunogenic and induce CTL re-
sponses more readily and earlier after viral infection. These
findings therefore have important implications for pro-
phylactic and therapeutic vaccine design and testing and
also for immunotherapy of treated primary infection.
These longitudinal studies also allowed for analysis of the
effects of HAART on CTL activity in acute and early
HIV-1 infection. We observed an increase in the number
of subjects with detectable HIV-1–specific CTL responses
after initiation of HAART that was also associated with an
increase in magnitude and breadth of preexisting CTL re-
sponses. The increase was more pronounced in individuals
treated before seroconversion, in whom CTL magnitude
more than doubled after initiation of HAART. The initial
increase in CTL frequencies after initiation of HAART
may be due to different factors. The drop in viremia after
effective antiretroviral treatment may lead to redistribution
of T cells from the lymphoid tissue to the peripheral circu-
lation (57, 58) allowing for the detection of higher HIV-1–
specific CTL responses in peripheral blood. Furthermore, it
required several weeks of effective treatment for viral loads
to decline below levels of detection, potentially providing
an antigenic stimulus for the development of new CTL re-
sponses during this period. In contrast, once viral load was
suppressed below the limit of detection (,50 copies HIV-1
RNA per ml plasma), virus-specific CTL responses started
to decline in both groups with primary infection. This
study did not allow for the analysis of virus-specific CTL
responses in chronically infected individuals after initiation
of HAART. However, a decline of CTL responses has
been described in chronically infected patients after initia-
tion of antiretroviral therapy (59, 60), suggesting that the
decline in HIV-1–specific CTL responses is a general phe-
nomenon, independent of the time antiretroviral treatment
is initiated. Further longitudinal comparative studies will be
required to determine if the rate of decline is similar in
these groups.
CD81 T cell activity against HIV-1 in early infection has
been reported previously in several studies, indicating that
CTLs are important in the initial drop in viremia. The
more detailed studies presented here, which include an as-
sessment of the specific epitopes targeted over time, show
that during acute HIV-1 infection, before HIV-1 serocon-
version, broader HIV-1–specific CTL responses were asso-
ciated with lower viral loads, suggesting that these re-
sponses are functionally relevant. In contrast, this inverse
correlation between viral load and breadth of CTL re-
sponses was lost in individuals treated later during in-
fection. Several factors may be contributing to this ob-
servation. It has been described that HIV-1 escapes from
CTL-mediated immune pressure early after primary infec-
tion by the generation of escape variants (25–29). The gen-
eral variability of HIV-1 can be addressed by analyzing the
relative diversity of HIV-1–Env by the HMA (47). Using
this assay, it was shown that the viral population is typically
homogenous in individuals treated before HIV-1 serocon-
version, but significantly greater diversity occurs in individ-
uals treated after HIV-1 seroconversion, even within the
first 180 d after infection.
In conclusion, HIV-1–specific CTL responses are rela-
tively modest and narrowly directed in individuals with
acute HIV-1 infection treated before HIV-1 seroconver-
sion, but early treatment allows for the generation of strong
HIV-1–specific T helper cell responses and the conserva-
tion of a very homogeneous virus population. In these in-
dividuals, an inverse correlation between breadth of CTL
responses and viral load was observed. In contrast, virus-
specific T cell help is lost and the virus population is highly
diversified in individuals treated later in HIV-1 infection.
In these individuals, no inverse correlation between CTL
and viral load was observed even with overall stronger
CTL responses, suggesting a complex interaction between
viral diversity, virus-specific T helper cells and CTLs in
HIV-1 infection. These findings provide new insights in
the dynamic changes during acute HIV-1 infection and
suggest that patients treated early versus those treated later
in infection suffer from distinct deficiencies. Individuals
treated in early infection may benefit from strategies aimed
at enhancing virus-specific CTL responses, whereas indi-
viduals treated later in infection may benefit from strategies
aimed at enhancing HIV-1–specific T helper cell functions
as well as broadening CTL responses to combat increased
viral diversity.
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